Tirzepatide Cost in the US

Why there’s no single “tirzepatide price”

If you search for what tirzepatide costs, you’ll find numbers ranging from $25 to over $1,000 a month — all current, all correct, all for the same medicine. That’s not a glitch. Tirzepatide’s price in the US in 2026 is set less by the drug itself than by two things: which brand you’re prescribed, and how you pay for it.

Get those two variables straight and the confusing spread of numbers resolves into a fairly clear picture. This page is the molecule-level overview — the map. For the full detail on each brand, the brand-specific pages (linked below) go deeper.

Note: Older guides quote “$150–400 a month” for tirzepatide. That was the compounded price during the 2022–2024 shortage. The FDA has since declared the shortage resolved and broad compounding has largely ended, so that figure no longer describes how most people legally access tirzepatide today. We cover what changed further down.

The two brands are the same drug

Tirzepatide is sold under two FDA-approved brand names, both from Eli Lilly:

• Zepbound — approved for chronic weight management (and, more recently, obstructive sleep apnea).
• Mounjaro — approved for type 2 diabetes.

They contain the identical active molecule, in the identical dose strengths, and their list prices are nearly the same. So why does the brand matter for cost? Because insurance coverage and the available savings programs follow the indication, not the molecule. Plans that won’t touch a weight-loss drug will often cover the same drug for diabetes. A savings card designed for one brand can’t be used on the other. The medicine is the same; the financial machinery around it is not.

This is the single most useful thing to understand before comparing prices: a quote you see online is only meaningful once you know which brand and which payment route it describes.

List price: the sticker almost nobody pays

At full list price — the manufacturer’s wholesale acquisition cost before any insurance, rebate, or discount — both brands sit around $1,080 a month for a 28-day supply, the same across every dose strength:

• Zepbound: roughly $1,086 per month.
• Mounjaro: roughly $1,080 per month (Lilly’s published figure is about $1,079.77).

Two things to know about this number. First, it’s identical regardless of whether you’re on a low starting dose or the highest strength — you’re paying for the box, not the milligrams. Second, almost no one actually pays it. The list price is the top of a stack that includes wholesaler markups, pharmacy-benefit-manager rebates, and patient programs. It mostly matters as the figure that every discount is measured against.

The routes that actually set your price

In practice, what you pay comes down to which of these lanes you fall into.

Commercial insurance + a manufacturer savings card

If you have commercial (employer or marketplace) insurance that covers your prescribed brand, Lilly’s savings card can bring your out-of-pocket cost down to as little as $25 a month. There are caps — a per-fill maximum and an annual ceiling — and the card is strictly for the on-label use (Zepbound for weight management, Mounjaro for diabetes).

The hard limit: savings cards are commercial-insurance only. Anyone on Medicare, Medicaid, TRICARE, VA, or other government coverage is excluded by federal anti-kickback rules, with no workaround. The cards also can’t be stacked on top of the cash-pay programs below.

LillyDirect self-pay vials

For people paying cash — no insurance, or insurance that won’t cover the drug — Lilly sells Zepbound single-dose vials directly through its LillyDirect platform at well below retail. As of late February 2026, that pricing is:

• $299/month for the 2.5 mg starter,
• $399/month for 5 mg,
• $449/month flat for 7.5 mg and every higher strength — provided you refill within 45 days of your prior delivery.

Miss that 45-day window on the maintenance doses and the price for that refill reverts to a higher standard rate (rising with strength) before you can re-enroll. The $449 ceiling is itself a 2026 change; higher-dose vials previously cost more. The trade-offs: these are vials you draw with a syringe, not pre-filled pens, and because it’s a cash program you can’t bill it to insurance or count it toward a deductible.

Mounjaro is being added to Lilly’s direct self-pay channel as well, but a firm per-dose Mounjaro cash figure was still settling as of mid-2026 — and the widely quoted $299/$399/$449 numbers belong to Zepbound, not Mounjaro. The brand-specific pages carry the current detail.

Medicare and the new GLP-1 Bridge

Medicare has historically excluded weight-loss drugs by statute, which left Zepbound uncovered for most beneficiaries. That changes on July 1, 2026, when a new Medicare GLP-1 Bridge begins covering Zepbound (the KwikPen) at a $50 monthly copay for people who qualify on BMI and clinical criteria. Worth knowing: the bridge covers the pen, not the self-pay vials, and people already covered for sleep apnea may not be eligible.

Mounjaro for type 2 diabetes is a different story — it’s generally covered under Medicare Part D today, with the actual cost depending on your plan’s formulary tier and where you are in the benefit year. The 2026 Part D out-of-pocket cap (around $2,000) limits the annual exposure.

TrumpRx and direct-to-consumer pricing

A new federal direct-purchase platform, TrumpRx, launched in February 2026 as part of pricing agreements with Lilly and Novo Nordisk. Through it, Zepbound is offered to cash payers in roughly the $300–$346/month range, and the agreements cap GLP-1 copays for many Medicare and Medicaid beneficiaries at about $50/month. As with other cash routes, direct purchases generally don’t count toward insurance deductibles or out-of-pocket maximums. The mechanics of these programs are evolving quickly; we keep the detail on a dedicated page.

Patient assistance for low income

For uninsured patients who meet income limits, Lilly’s patient-assistance foundation can provide tirzepatide at little or no cost. This is a slower, eligibility-gated route, but for those who qualify it’s the lowest-cost legitimate option of all.

What about compounded tirzepatide?

This is where the biggest 2026 shift sits. During the 2022–2024 shortage, compounding pharmacies could legally make tirzepatide copies, and telehealth platforms sold them for a few hundred dollars a month. That’s the era those old “$150–400” figures came from.

It has largely ended. The FDA declared the tirzepatide shortage resolved in December 2024, and the enforcement discretion that allowed mass compounding closed in 2025 — for state-licensed 503A pharmacies in February and for 503B outsourcing facilities in March, a position a federal court upheld in May 2025. In April 2026 the FDA went further, proposing to remove tirzepatide from the 503B bulk-substances list entirely.

What remains is narrow: patient-specific 503A compounding, only where an individual has a documented clinical need an approved product can’t meet — and the FDA has stated plainly that wanting a lower price or more convenience does not count as that need. On top of the legal narrowing, compounded and gray-market product has drawn repeated safety concerns: sub-potent samples, contamination, and a novel impurity Lilly flagged in early 2026. Vials sold online as “research use only” are not for human use and sit outside any legitimate access route. The takeaway for a cost comparison: compounded tirzepatide is no longer the routine budget option it was, and treating it as one in 2026 means accepting real legal and safety exposure.

For the full regulatory blow-by-blow, see the compounding-status page linked below.

Is there a generic? Not for years

There is no FDA-approved generic tirzepatide, and there won’t be one soon. Lilly’s patents on the molecule run into the mid-2030s, so a true generic or biosimilar — the kind of competition that eventually collapses a drug’s price — is likely a decade away. This is why the manufacturer programs above, not the open market, are what actually move the price today.

Putting it together: a realistic 2026 picture

For most people in 2026, the honest answer to “what does tirzepatide cost” is one of these:

• About $25/month if you have commercial insurance that covers your brand and you use the savings card.
• About $299–$449/month cash through LillyDirect self-pay vials, depending on dose and on staying within the refill window.
• About $50/month for qualifying Medicare beneficiaries once the GLP-1 Bridge starts (Zepbound) or under existing Part D coverage (Mounjaro for diabetes).
• Around $300–$346/month through TrumpRx as a cash route.
• $0 or near it for low-income uninsured patients who qualify for patient assistance.
• About $1,080/month only if you somehow pay full list with no program at all — which is rare.

Which of those applies to you depends mostly on your insurance and which brand you’re prescribed. Start there, then read the brand pages for the precise numbers.

This page is for general education about pricing and access. It isn’t medical advice, doesn’t recommend a specific product or dose, and prices and program rules described here are current as of the date above and can change.